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Abstract: Inadequate supply of oxygen (O2) is a hallmark of many diseases, in particular those related
to the cardiovascular system. On the other hand, tissue hypoxia is an important factor regulating
(normal) embryogenesis and differentiation of stem cells at the early stages of embryonic development.
In culture, hypoxic conditions may facilitate the derivation of embryonic stem cells (ESCs) and
the generation of induced pluripotent stem cells (iPSCs), which may serve as a valuable tool for
disease modeling. Endothelial cells (ECs), multifunctional components of vascular structures, may be
obtained from iPSCs and subsequently used in various (hypoxia-related) disease models to investigate
vascular dysfunctions. Although iPSC-ECs demonstrated functionality in vitro and in vivo, ongoing
studies are conducted to increase the efficiency of differentiation and to establish the most productive
protocols for the application of patient-derived cells in clinics. In this review, we highlight recent
discoveries on the role of hypoxia in the derivation of ESCs and the generation of iPSCs. We also
summarize the existing protocols of hypoxia-driven differentiation of iPSCs toward ECs and discuss
their possible applications in disease modeling and treatment of hypoxia-related disorders.
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1. Introduction
The fundamental importance of adequate oxygenation for the functioning of aerobic organisms
has been recognized for centuries, and the efforts to understand the molecular mechanisms of cell
sensing and adopting to oxygen availability were awarded the 2019 Nobel Prize in Physiology or
Medicine, to William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza [1]. Embryonic
development and the maintenance of adult homeostasis is dependent on the delivery of adequate
O2 and nutrients to cells in the body via a functional vascular system. In contrast to atmospheric
oxygen concentration (21%), its level in tissues is much lower and varies between organs. However,
when it decreases below the standard values, tissue metabolism is compromised. To overcome the
detrimental effects of hypoxia/ischemia the molecular machinery involving transcriptional activation
of hypoxia-dependent genes, including vascular endothelial growth factor (VEGF, VEGF-A) and basic
fibroblast growth factors (bFGF, FGF2) is triggered. Of importance, inadequate response to low
O2 concentration can lead to damage in many aspects of cardiovascular development. Moreover,
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during the progression of various vascular diseases, the rescue mechanisms are often ineffective,
and aberrations in the hypoxic response greatly contribute to serious human ischemia-related diseases.
Endothelial cells (ECs), building blood vessels, play a pivotal role in maintaining vascular
homeostasis, and their improper functioning contributes to the progression of vascular-related diseases.
Therefore, understanding the biology of these cells in hypoxic conditions, as well as, exploring
the role of O2 in regulating cardiovascular events during early embryonic development may be
helpful for better diagnosis and treatment. Of note, the development of human induced pluripotent
stem cells (hiPSCs) [2] has opened a new era in the studies of molecular aspects of human diseases.
The similarity of hiPSCs to human embryonic stem cells (hESCs), especially when (high) pluripotency
potential is evaluated, makes these cells relevant to model developmental disorders. Importantly,
in contrast to hESCs, the usage of hiPSCs does not raise so many ethical questions, although still
some issues, particularly in the context of human reproductive cloning, or generation of human
gametes, are debated [3]. Patient-specific hiPSCs may provide mechanistic insights into specific
disorders, also those which are hypoxia-driven. They have other numerous biomedical applications in
basic research and after directed differentiation into derivatives of all three germ layers can serve as a
platform for drug testing.
2. Molecular Basis of Oxygen Sensing
The heterodimeric transcription factor hypoxia-inducible factor (HIF) is the pivotal regulator of
molecular response to low oxygen tension. In most vertebrates, three distinct members are found.
Two major isoforms, HIF-1 and HIF-2, which share some similarities but show distinct properties,
including the kinetics of activation and oxygen dependence, are known to regulate oxygen homeostasis
influencing embryonic development, postnatal physiology as well as disease pathogenesis [4]. It was
reported that HIF-1α drives the response to acute hypoxia and decay during prolonged hypoxia,
whereas HIF-2α predominantly controls the reaction to chronic hypoxia. Moreover, HIF-2α is more
stable compared to HIF-1α at higher oxygen levels (5% O2) in neuroblastomas [5,6] (Figure 1A).Biomolecules 2020, 10, 1614 3 of 30 
 
Figure 1. The stabilization of hypoxia-inducible factors (HIFs) under hypoxic conditions and main 
transcriptional targets. (A) HIF-1 is responsible for acute response, whereas HIF-2 mediates chronic 
reaction. (B) In normoxic conditions, the HIF-α subunit undergoes degradation pathways. When the 
O2 level decreases, HIF-α is stabilized and together with the HIF-β subunit leads to the transcriptional 
induction of HIF-inducible genes (mentioned in the text) via binding to the hypoxia response element 
(HRE) sequence. 
3. Hypoxia in Early Embryonic Development and Vasculature Formation 
3.1. Early Embryogenesis Progresses in the Hypoxic Environment 
Embryonic development is a strictly regulated process that starts from the moment of egg cell 
fertilization and involves coordinated spatial and temporal changes in gene expression, cell division, 
migration, and cellular differentiation. Over the time of 8 weeks (duration of the embryogenesis in 
humans) a complex, however, not fully functioning organism grows out of a single-celled zygote [10]. 
Embryogenesis occurs in relatively hypoxic conditions due to the rapid cell proliferation as well as 
increased oxygen demand and consumption, which is not yet supported by the maternal circulation 
[11–13] (Figure 2). 
 
Figure 2. The role of hypoxia during embryonic development and vasculature formation. Embryonic 
development occurs in hypoxia conditions. In the embryo, a low level of O2 stimulates the 
differentiation of stem cells, including hemangioblasts (from early mesoderm), and facilitates 
vasculogenesis and angiogenesis through HIF-dependent mechanisms. 
Figure 1. The stabilization of hypoxia-inducible factors (HIFs) under hypoxic conditions and main
transcriptional targets. (A) HIF-1 is responsible for acute response, whereas HIF-2 mediates chronic
reaction. (B) In normoxic conditions, the HIF-α subunit undergoes degradation pathways. When the
O2 level decreases, HIF-α is stabilized and together with the HIF-β subunit leads to the transcriptional
induction of HIF-i ducible genes (mentioned in the text) via binding to the hypoxia response element
(HRE) sequence.
The biology of the HIF-3 factor is still not fully discovered as its multiple variants being the result
of the utilization of various promoters, different transcription initiation sites, and alternative splicing
exist [7].
HIF binds to DNA via N-terminal basic helix–loop–helix (bHLH) domain and activates
transcription with the C-terminal transcriptional transactivation domain (TAD), whereas Per–Arnt–Sim
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(PAS) domain is required for the protein dimerization. This hypoxia-activated transcription factor
consists of two subunits, an oxygen-sensing HIF-α, the isoform undergoing constant degradation
under normal oxygen concentration through prolyl hydroxylases (PHDs)-dependent modification,
and an oxygen-independent HIF-β (aryl hydrocarbon receptor nuclear translocator, Arnt), expressed
at a constant level, irrespectively of oxygen status. In hypoxic conditions, HIF-α is stabilized
and heterodimerizes with the HIF-β subunit to form the active HIF transcription factor able to
trigger gene expression after binding to the hypoxia response element (HRE) in the promoter
region of hypoxia-target genes. These HIF-regulated genes involve those implicated in cellular
differentiation, metabolism, angiogenesis, etc. including VEGF and its receptors VEGFR1 (Flt1),
VEGFR2 (Kdr, Flk1) as well as FGF2, platelet-derived growth factor-β (PDGF-β), erythropoietin (EPO),
transferrin, glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and many others
(reviewed in more details in [8,9]) (Figure 1B).
3. Hypoxia in Early Embryonic Development and Vasculature Formation
3.1. Early Embryogenesis Progresses in the Hypoxic Environment
Embryonic development is a strictly regulated process that starts from the moment of egg cell
fertilization and involves coordinated spatial and temporal changes in gene expression, cell division,
migration, and cellular differentiation. Over the time of 8 weeks (duration of the embryogenesis in humans)
a complex, however, not fully functioning organism grows out of a single-celled zygote [10]. Embryogenesis
occurs in relatively hypoxic conditions due to the rapid cell proliferation as well as increased oxygen demand
and consumption, which is not yet supported by the maternal circulation [11–13] (Figure 2).
Biomolecules 2020, 10, 1614 3 of 30 
 
Figure 1. The stabilization of hypoxia-inducible factors (HIFs) under hypoxic conditions and main 
transcriptional targets. (A) HIF-1 is responsible for acute response, whereas HIF-2 mediates chronic 
reaction. (B) In normoxic conditions, the HIF-α subunit undergoes degradation pathways. When the 
O2 level decreases, HIF-α is stabilized and together with t e HIF-β subunit leads to the transcriptional 
induction of HIF-inducible genes (m ntioned in the text) via binding to the hypoxia response element 
(HRE) sequence. 
3. Hypoxia in Early Embryonic Development and Vasculature Formation 
3.1. Early Embryogenesis Progresses in the Hypoxic Environment 
Embryonic development is a strictly regulated process that starts from the moment of egg cell 
fertilizatio  and involves coordinated spatial and temp ral changes in gene expression, cell division, 
migration, and cellular d fferentiation. Over the time of 8 weeks (duration of the embryogenesis in 
humans) a complex, however, not fully functioning organism grows out of a single-celled zygote [10]. 
Embryogenesis occurs in relatively hypoxic conditions due to the rapid cell proliferation as well as 
increased oxygen demand and consumption, which is not yet supported by the maternal circulation 
[11–13] (Figure 2). 
 
Figure 2. The role of hypoxia during embryonic development and vasculature formation. Embryonic 
development occurs in hypoxia conditions. In the embryo, a low level of O2 stimulates the 
differentiation of stem cells, including hemangioblasts (from early mesoderm), and facilitates 
vasculogenesis and angiogenesis through HIF-dependent mechanisms. 
Figure 2. The role of hypoxia during embryonic development and vasculature formation. Embryonic
development occurs in hypoxia conditions. In the embryo, a low level of O2 stimulates the differentiation
of stem cells, including hemangioblasts (from early mesoderm), and facilitates vasculogenesis and
angiogenesis through HIF-dependent mechanisms.
Measurements performed in different mammalian species revealed that oxygen concentration
in oviductal and uterine lumen varies from 1.5% (uterus of rhesus monkey) to 8.7%
(e.g., rabbit oviduct and uterus) [14]. Interestingly, in hamsters and rabbits, the level of hypoxia
depends on the reproductive stage decreasing significantly at the time of blastocyst formation and
implementation [14]. This indicates that the pre-implemented embryo has to be adapted in vivo to
low oxygen availability. In accordance, several studies confirmed the beneficial effects of hypoxia
during the initial stages of mammalian blastocyst development performed in vitro. The number of
goat embryos, for instance, isolated at 2- to 4-cell stage, which progressed into expanded and/or
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hatched blastocyst was significantly higher when cultured in 7% oxygen in comparison to normoxic
counterparts [15]. A similar effect was also observed in sheep and cows. Detailed analyses of the latter
species revealed that bovine embryos engage the HIF-2α transcription factor to detect and respond to
hypoxic conditions. Particularly, the application of 2% oxygen resulted in the upregulation of glucose
transporter 1 (GLUT1) expression indicating metabolic adaptation, when compared to 7% and 20% O2
concentrations. In parallel, translocation of HIF-2α into the nuclei of inner mass-forming cells was
observed followed by their higher number, which could be associated with better in vivo post-transfer
outcomes [16]. On the other hand, Pabon et al. reported that even short-term exposure of murine
zygotes to a normoxic environment can impair their further development, whereas no changes were
observed when 5% oxygen conditions were applied [17].
Due to the ethical restrictions, a detailed investigation of the environmental conditions, including
the effect of hypoxia during the early stages of human embryonic development, has been limited to
fertilized oocytes generated during assisted reproductive technologies (ART). Particularly, in vitro
culture of such human embryos for 3 (up to 8-cell stage) to 6 (blastocyst stage) days is an intrinsic
step of ART where applied conditions may strongly influence the implementation success upon
in vivo transfer [18]. Indeed, Peng et al. reported that maintaining the developing zygote in 5%
oxygen resulted in increased potential to form high-quality embryos and improved implementation
rate in comparison to normoxic culture. However, the final pregnancy rate was not significantly
different between both conditions [19]. Similarly, a meta-analysis of studies describing the application
of hypoxia for ART revealed inconclusive results. Some clinical trials reported a positive effect of
low oxygen concentration on the implementation. However, no differences in pregnancy rate were
observed regardless of the stage of embryo transfer (either at day 2/3 or 5/6) [18]. In a large prospective
randomized study in which more than one thousand in vitro fertilized oocytes were placed either in
ambient or reduced oxygen level, no effect of hypoxic conditions on fertilization, embryo development,
implementation, and pregnancy rate were reported. Interestingly, surplus embryos maintained at 5%
O2 demonstrated the increased potential to reach the blastocyst stage in vitro due to the detrimental
effect of normoxic conditions on the cell number on days 5–6 of development [20]. Thus, hypoxia
may positively affect the preimplantation embryonic viability, but this effect is not strong enough to
influence the further pregnancy rate upon in vivo transfer. Adding to the complexity of this issue,
the application of in vitro method mimicking the implementation phase of human embryogenesis
described by the group of Zernicka-Goetz, revealed that the hypoxic environment did not sustain the
proper transition of inner cell mass of pluripotent cells (day 5–6) into epiblast phenotype (day 9–10 of
embryonic development). Instead, cell death during the implementation stage was observed possibly
due to increasing embryo size, leading to decreased oxygen availability inside the embryo [21].
3.2. ‘Physiological Hypoxia’ as a Driving Force of Vasculature Development
As indicated earlier, hypoxia is a driving force of early blastocyst development, but it also plays a
key role in controlling further events during embryogenesis, including vasculature formation. In 2001,
Lee et al. demonstrated, by intravenous administration of the hypoxia marker, pimonidazole, to the
pregnant mouse, strongly hypoxic regions (but with the spatial and temporal existence) in developing
tissues of normal embryos in vivo [22]. Of note, hypoxic areas were characterized by the colocalization
of HIF-1α and VEGF. Moreover, the concomitant presence of the platelet endothelial cell adhesion
molecule-1 (PECAM1) positive cells led to the later confirmed hypothesis that “physiological hypoxia”
is orchestrating the development of the circulatory system that precedes all other systems [22].
As HIFs are well known transcriptional regulators of the cellular response to low oxygen levels,
their involvement in vasculature development during embryogenesis has been extensively studied.
Mice globally lacking Hif1a were shown to die by embryonic day 10.5 due to cardiovascular impairment
and defects in blood vessel formation [23]. Similarly, Hif1b (Arnt−/−) knockout animals showed
lethality around embryonic day 10.5 due to vascular abnormalities. Moreover, Arnt-deficient embryos
demonstrated decreased VEGF mRNA and protein levels that showed the importance of the VEGF
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signaling during embryonic vascularization [24]. Furthermore, to confirm the role of HIFs specifically
in endothelial cells transgenic mice expressing dominant-negative HIF mutant (HIFdn) only in the
vasculature were created. Such animals were characterized by the inhibition of the transcriptional
responses mediated by both HIF-1 and HIF-2 and died around embryonic day 11.5. In these embryos,
very primitive vasculature could be detected together with severe cardiovascular defects [25]. All these
examples show the important role of hypoxia on ECs proper function and development during
embryo growth.
Similarly to embryogenesis, placental development is also associated with hypoxic conditions.
The human placenta is formed from a stem cell population termed cytotrophoblasts which proliferate
in an undifferentiated state, preferably in a hypoxic microenvironment (2.4% oxygen) than a normoxic
milieu [26]. Moreover, the role of HIFs seems to be especially important in this process as placentas
from Arnt−/− and Hif1a−/−Hif2a−/− embryos exhibit strongly defective vascularization. Moreover, in the
absence of HIFs, trophoblast lineage determination is altered [27]. Importantly, the lower oxygen
concentration not only initiates the development of the placenta and embryo but also protects the
growing organism against the harmful effects of oxidants [28].
3.3. Vascular Development during Embryogenesis
The formation of the vasculature network precedes all other systems and the first sign of blood
vessel formation can be observed as early as embryonic day 7.5 in the extra-embryonic blood islands of
the yolk sac [29]. ECs are derived from the mesoderm [30], and during embryogenesis, the vasculature
is formed via two distinctive mechanisms: vasculogenesis and angiogenesis. Vasculogenesis is
the de novo assembly of the blood vessels from the endothelial precursors, known as angioblasts,
and is responsible for the primary vascularization of the developing organs. Further maturation,
which involves branching and sprouting of preexisting vessels, occurs via a more complex angiogenesis
process [31,32]. Finally, the addition of supporting cells, like pericytes and smooth muscle cells leads
to the formation of a fully functioning vascular network [33,34]. Subsequent vasculature expansion,
remodeling, and specialization results in the creation of a circulatory system consisting of arterial,
venous, and lymphatic vessels [35].
Over the years, many factors have been described to play a pivotal role in the process of blood
vessel formation, including responsibility for the formation of angioblasts from mesenchymal cells
by FGF2, pro-proliferative and pro-migratory VEGF with its receptors, and angiopoietin-1 (Ang-1),
which stimulates the recruitment of the blood vessel supporting cells. Knockout of any of the mentioned
factors leads to severe vessel malformation, a strong aberration of ECs function, or even death of the
embryo during pregnancy [36–41]. Importantly, the expression of all of the factors can be regulated by
the HIFs, suggesting that the development of a properly functioning circulatory system will depend
on the subtle changes in the oxygen levels in tissues [26].
3.4. Endothelial Cell Origin and Differentiation
EC origin during embryogenesis was the topic of many studies. Despite the occurrence of some
misleading theories, it is broadly accepted nowadays that ECs and hematopoietic cells share a common
precursor, called hemangioblast [29]. Close developmental association and gene targeting studies
showing that both endothelial and hematopoietic precursors are characterized by the expression of
common markers, such as PECAM1, VEGFR2, CD34, stem cell leukemia (SCL), GATA-binding factor
2 (GATA2), strengthened this hypothesis [42,43].
In the beginning, the generation of the hemangioblasts from mesodermal cells occurs in the
response to the bone morphogenetic protein-4 (BMP4), and by the activation of GATA2, a hematopoietic
transcription factor, leading to the increased expression of VEGFR2 and SCL, two critical factors for
further lineage development [44,45]. In response to VEGF signaling, hemangioblasts proliferate and,
depending on the presence of appropriate factors, differentiate in either endothelial or hematopoietic
progenitors. VEGF signaling is extremely important as VEGFR2 deficiency leads to the absence of
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proper blood vessels and embryo lethality [37]. Interestingly, the presence of the VEGFR2 at the very
beginning of the hemangioblast differentiation suggests that hematopoietic cell progenitors originate
from the endothelial intermediate cells, called hemogenic ECs [46]. It can be further supported by the
increased expression of typical endothelial markers, such as Tie2, CD144 (VE-cadherin), and PECAM1
during the first steps of hemangioblast generation. In the course of hematopoietic cell differentiation,
expression of VEGFR2 is downregulated with the simultaneous upregulation of CD45 marker, Runx-1
(AML1) transcription factor, and many others [47,48].
The main source of VEGF during embryogenesis comes from the O2-deprived cells, suggesting
the important role of the hypoxic conditions in the differentiation of ECs. Indeed, it was shown
that hypoxia leads to an increased number of hemangioblasts. Moreover, under conditions of low
oxygen concentration, expression of mesodermal T-box gene Bry and BMP4 crucial for hemangioblast
development was induced one day earlier than it was observed in normoxia [49].
3.5. Endothelial Cell Commitment and Autophagy
A low oxygen level was also described to be crucial for the further steps of EC development,
meaning venous or arterial commitment. In the beginning, ECs have a default venous identity with
the expression of VEGFR3 (FLT4, the receptor for VEGF-C and VEGF-D, other members of VEGF
family) and downregulated arterial Notch signaling [50,51]. One of the factors responsible for the
activation of the Notch pathways is VEGF. Such activation leads to the downregulation of the Flt4
gene and the upregulation of the various arterial markers. Therefore, a low level of oxygenation,
followed by HIF and VEGF activation, will promote the arterial commitment of the ECs [52]. Moreover,
in 2013, the group of Wang et al. [53] demonstrated that the autophagy process is upregulated under
hypoxic conditions promoting survival of the endothelial precursors via inhibition of apoptosis.
When autophagy was inhibited using 3-methyladenine (3-MA), the hypoxic environment increased
the number of apoptotic cells. Contrary, the induction of autophagy using rapamycin reduced the
number of apoptotic endothelial progenitors [53].
As hypoxia seems to be one of the important factors regulating the fate of ECs during
embryogenesis, it seems understandable that the modification of the oxygen level might serve
as a potential modulator of ECs differentiation in vitro.
4. Hypoxia in the Derivation of Human Embryonic Stem Cells and Generation of induced
Pluripotent Stem Cells
4.1. Hypoxia and hESC Culture
As the investigation of the environmental conditions during the early stages of human embryonic
development is not ethically acceptable, a more detailed understanding of the mechanisms involved
in this process became possible due to the development of methods for the isolation of murine
and then human embryonic stem cells (mESCs and hESCs, respectively). For mouse embryos,
these conditions were described independently in 1981 by Martin Evans and Matthew Kaufman as
well as Gail Martin [54,55]. Cells building the inner mass of the murine blastocyst can be cultured
in vitro while maintaining their pluripotency, i.e., the ability to differentiate into three germ layers
(endo-, meso- and ectoderm). However, to sustain this state, a feeder cell layer is needed. It is usually
composed of mitotically inactivated mouse embryonic fibroblasts (MEF), which secrete leukemia
inhibitory factor (LIF) activating transcription factors crucial for mESCs growth [56]. On the other hand,
these cells, deprived of appropriate in vitro culture conditions, begin the process of differentiation.
Due to such properties, the ESC-based system allows for a detailed investigation of signaling pathways
and transcription factors participating in various stages of specialization of different cell types including
the role of hypoxia and HIFs in ECs development.
The first hESC line was isolated by Thomson et al. in 1998 [57]. Interestingly, these cells require
different in vitro culture conditions than mESCs, maintaining the characteristics of stem cells in the
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presence of FGF2 and transforming growth factor β (TGF-β) (reviewed in: [58]). Further studies
showed that at the level of gene expression profile and growth requirements, they resemble the
so-called epiblast stem cells (EpiSCs) isolated from mouse epiblast at the stage of gastrulation [59].
Stimulation with FGF2 and TGF-β factors provides them with the ability to self-renew and differentiate
to all three germ layers in vitro and in vivo after administration to mice with the impaired immune
system - under these conditions, they form teratomas, i.e., tumors composed of ectoderm-, endoderm-,
and mesoderm-derived tissues. As such, conventional hESCs have been described to demonstrate the
so-called primed state (in contrast to naïve, characteristic to inner cell mass of the pre-implementation
blastocyst) in which female lines undergo X chromosome inactivation (XCI) [60]. Nonetheless,
Lengner et al. reported that isolation of hESCs in 5% O2 can inhibit this process and maintain
two active X chromosomes in the cells. Further analyses revealed that oxidative stress associated
with normoxic culture conditions was responsible for increased XIST (X-inactive specific transcript)
expression inducing the XCI. Interestingly, deferoxamine, a potent stabilizer of HIF transcription
factors, was described within the compounds inhibiting the detrimental effect of atmospheric oxygen
concentration on XIST upregulation [60].
In accordance, the first methods of hESC culture were associated with pronounced spontaneous
differentiation requiring manual picking of undifferentiated cells or constant early passaging,
which sustained the proper ratio of pluripotent cells [57,61]. Appreciating the role of hypoxic
conditions in mammalian pre-implementation embryonic development, Ezashi et al. assessed the
effect of low oxygen concentration on hESC culture. The results indicated that maintaining the hESCs
at 5% O2 or below significantly reduced the area of differentiated cells within the inspected colonies.
A similar beneficial effect was also observed for the efficiency of embryoid bodies (EB) formation [61],
genetic stability, and clonal recovery [62]. Detailed transcriptomic analysis of hESCs cultured for
ten passages in 2% oxygen revealed activation of gene expression pattern characteristic for hypoxic
conditions as well as pathways associated with development and differentiation [63]. Similar results
were obtained for cells maintained at 4% O2 with a profound hypoxia-related transcriptional profile,
which was involved in the control of pluripotency and hESC differentiation. Interestingly, MYC,
encoding the c-MYC transcription factor crucial for self-renewal of pluripotent stem cells, was detected
among the upregulated transcripts and its expression remained high after prolonged culture in hypoxic
conditions, possibly sustaining the undifferentiated phenotype of hESCs [64]. Further analyses revealed
that among HIF isoforms, HIF-2α was responsible for the activation of MYC transcription under low
oxygen levels. Noteworthy, we have previously described a similar cross-talk between HIF-2α and
c-MYC in human ECs, which is a part of the mechanism controlling interleukin 8 (IL-8) expression in
hypoxia [65]. The level of IL-8, however, decreases in severe (0.5%) and mild (5% oxygen) hypoxic
conditions due to the predominant negative regulation of c-MYC by HIF-1α indicating the interplay
between both HIF isoforms in different cell types [65]. Interestingly, Forristal et al. added another layer
of complexity to this issue, describing the HIF-3α-mediated upregulation of HIF-2α and concomitant
downregulation of HIF-1α in hESCs cultured under low oxygen tension [66]. The study, on the
other hand, confirmed the crucial role of HIF-2α in pluripotent stem cells as its silencing resulted in
decreased expression of OCT4, SOX2, and NANOG, which constitute crucial transcription factors
for maintaining the pluripotent phenotype of hESCs, together with the increased level of SSEA1,
an early differentiation marker [66]. This observation was further strengthened by a recent study
linking hypoxia, metabolism, and the expression of pluripotency-mediating factors. Particularly, it was
reported that glycolytic flux in hESCs cultured under 5% oxygen controls the level of HIF-2α, which in
turn directly upregulates C-terminal binding protein 1 and 2 (CTBP1 and 2, respectively) transcription
factors promoting self-renewal of hESCs [67]. HIF-2α was also demonstrated to provide the higher
activity of glycolytic flux through activation of the expression of GLUT1 in these cells [68].
Application of mESCs in which HIF-1α expression was replaced with the 2α isoform
(Hif-1αHif-2αKI model) revealed that the level of OCT4 is also regulated by HIF-2α during early
embryogenesis in mouse [69,70]. Interestingly, teratomas formed by such cells were characterized
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by increased expression of VEGF and microvessel density, which highlighted the role of HIF-2α in
vasculature formation during embryonic development [69].
4.2. Hypoxia and the Generation of iPSCs
Although the derivation of hESC lines provided a novel path toward the application of stem
cells for investigation of human embryonic development as well as the generation of different cell
types for drug screening and regenerative medicine, the research progress has been hampered by
ethical concerns regarding the destruction of human embryos during hESC isolation [71]. Additionally,
the availability of patient-specific hESCs was highly limited, restricting their utilization in disease
modeling, while the possibility of immune rejection upon in vivo administration of hESC-derived cells
raised concerns over successful outcomes of clinical trials. Thus, the breakthrough in the field occurred
after the description of the somatic cell reprogramming method with defined transcription factors.
In 2006 Takahashi and Yamanaka demonstrated that overexpression of as little as four proteins,
namely Oct4, Sox2, Klf4, and c-Myc, which regulate self-renewal and developmental potential of ESCs,
in MEFs was enough to obtain a small proportion of cells with ESC-like morphology, gene expression
profile, and differentiation potential. Due to the method of generation, they were called induced
pluripotent stem cells (iPSCs) and could be maintained in culture in the same conditions as applied to
mESCs [72]. Importantly, a year later, the same group reported that the identical set of transcription
factors (called Yamanaka’s cocktail) reprogrammed human adult fibroblasts. Subsequent progress in
the application of hiPSCs confirmed that the reprogramming method provides invaluable opportunities:
(i) to obtain patient-specific stem cells and differentiate them into cells affected by the patient’s disease,
(ii) to utilize such differentiated cells in drug testing, (iii) to generate donor-specific cells applicable
in regenerative medicine and (iv) to study in vitro the mechanisms of stem cells differentiation.
The iPSC-based strategy may be combined with the CRISPR/Cas9 approach to repair the mutations in
specific genes allowing the unprecedented chance for personalized investigations (Figure 3). The initial
efficiency of mouse iPSCs (miPSCs) and particularly human iPSCs (hiPSCs), however, was very low,
which triggered the search for favorable conditions increasing the rate of successful reprogramming.
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Figure 3. General scheme of induced pluripotent stem cells-endothelial cells (iPSC-ECs) utilization. 
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Figure 3. General scheme of induced pluripotent stem cells-endothelial cells (iPSC-ECs) utilization.
Patient somatic cells may be used to obtain iPSC after delivery of Yamanaka’s cocktail of four
transcription factors (Oct4, Sox2, Klf4, c-Myc), however, the process may be facilitated by hypoxia.
After iPSC reprogramming and differentiation of iPSCs to ECs, the cells may be used in various
applications. Low oxygen tension may also trigger vascular differentiation. The possibility to modify
(correct) mutations in patient-specific iPSCs using CRISPR/Cas9 technology creates a unique opportunity
for personalized investigations.
Taking into consideration the important role of physiological oxygen tension for maintaining the
undifferentiated phenotype of hESCs and on the function of other stem cell populations, Yoshida et al.
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demonstrated as early as in 2009 that hypoxia significantly increases the efficiency of both miPSCs and
hiPSCs generation).
The most profound effect was observed for the propagation of the reprogramming process in 5%
O2 concentration. Interestingly, such conditions provided a higher rate of miPSC generation even
after the transduction of MEFs with only two transcription factors—Oct4 and Klf4 [73]. The beneficial
role of hypoxia on the reprogramming outcome of human fibroblasts was further confirmed by
Mathieu et al., who additionally performed a detailed analysis of HIF-1α and HIF-2α activity during
hiPSC development [74]. Of note, both HIF isoforms were transiently stabilized and transcriptionally
active during the reprogramming process even in normoxic conditions and thus the gene expression
changes observed in the transition from differentiated to pluripotent phenotype demonstrate a hypoxic
signature. Interestingly, HIF-2α was indispensable for the early phase of hiPSC generation, when
it mediated a switch from oxidative to glycolytic metabolism. In the later stages, its prolonged
stabilization, however, significantly decreased the reprogramming efficiency due to the upregulation
of TNF-related apoptosis-inducing ligand (TRAIL) and possibly downstream inhibition of caspase
3 activity. HIF-1α, on the other hand, did not exert such a biphasic effect and its stabilization was
necessary to induce the metabolic switch during hiPSC generation without the negative effect on
reprogramming outcome [74].
We have also confirmed that the reprogramming of murine fibroblasts in 5% oxygen substantially
increased the number of miPSCs colonies and alkaline phosphatase (miPSC marker) staining after
reprogramming (Figure 4). However, due to the cost of constant hypoxia maintenance as well as the
development of other approaches increasing the miPSCs and hiPSCs yield, low oxygen tension is
currently not routinely used for the generation of these cells.
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Figure 4. The influence of hypoxia on iPSC reprogra ing. Cells kept in low oxygen concentration
(5% O2) create more colonies (indicated by arrows) than cells cultured in atmospheric conditions
(21% O2) as showed by (A) representative photos; (B) their calculation as well as (C) alkaline phosphatase
(miPSC marker) staining after reprogramming.
5. Hypoxia and Stem Cell Differentiation toward ECs
Over the past years, significant advances have been made in generating ECs from a variety of
cellular sources and using a plethora of well-established protocols, which may differ in, among others,
efficiency, cost, or duration. Differentiation of ESCs or iPSCs into ECs is mostly performed using
coculture, EBs, and 2-dimensional monolayer methods (reviewed in [75]), (Figure 2). The discovery that
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hypoxia may trigger vascular differentiation of ESCs/iPSCs, as well as arterial specification, may result
in obtaining a higher yield of therapeutically relevant cells.
5.1. Hypoxia Facilitates Vascular Differentiation of Pluripotent Stem Cells
Low oxygen environment, better resembling physiological conditions, not only influences the
generation of pluripotent cells but also prominently modulates the differentiation toward ECs as
evidenced in several in vitro studies utilizing mESCs [76–78], hESCs [76,79–82], hiPSCs [82,83], as well
as other stem cell sources, such as glioblastoma stem-like cells [84]. Despite different experimental
schemes applying also various hypoxia levels, the results unequivocally emphasize the facilitation
of endothelial lineage commitment upon low oxygen concentration, mimicking the phenomenon
observed during early embryonic development. Such an approach might provide the source of ECs
not only for research purposes but potentially also for further therapeutic applications.
Already in 2007, the group of Chung et al. [85,86] found that the central region of hESCs-derived
human EBs (hEBs) is enriched in cells that express EC markers, including PECAM1, vWF, VEGFR1,
Tie2 (unlike cells growing in the outgrowth of hEBs), which can uptake acetylated low-density
lipoproteins (acLDL) and exhibit increased differentiation capacity toward EC lineage. Based on these
observations, the authors further hypothesized that hypoxic conditions may occur naturally in the
center region of hEBs [80]. Such an assumption was strengthened by the analysis of spontaneously
differentiating mouse EBs (mEBs), derived from mESCs, in which the hypoxic region was observed even
under normoxic conditions, as assessed using anti-pimonidazole adduct antibody [77]. Hence, several
studies investigated the impact of hypoxia as a driving force that accelerates vascular differentiation of
pluripotent stem cells.
Different experimental schemes were applied to directly compare the effect of low oxygen
environment (1–5% O2) and normoxic (21% O2) conditions. In general, an elevated abundance
of cells expressing typical endothelial markers (e.g., CD144, PECAM1, VEGFR1, Tie2), exhibiting
endothelial-like morphology (bundles of elongated cells and cobblestone area-forming cells) together
with improved functionality (formation of tubule-like structures on Matrigel, uptake of acLDL)
was observed upon low oxygen tension in various studies utilizing different sources of pluripotent
stem cells: mESCs or mEBs, hESCs or hEBs and hiPSCs cultured with or without the addition of
growth factors (summarized in Table 1). As a step forward, improved blood perfusion in ischemic
hindlimb and cardiac function after myocardial infarction (MI) in vivo in mice or rats injected with
ECs differentiated under hypoxic conditions was demonstrated [76,77,79].
Noteworthy, global transcriptome profiling of hESCs cultured under 1% and 5% O2 for 24 h, 5 days,
and 15 days further confirmed changes in the expression of genes associated with e.g., vasculogenesis,
angiogenesis, regulation of vascular permeability as well as vasodilatation and vasoconstriction [79].
Interestingly, White et al. [87] demonstrated that the method of ECs differentiation in which hESCs
and hiPSCs were cultured and initially differentiated under hypoxic conditions (5% O2) yielded
large numbers of ECs with limited gene expression variation between hESC- and hiPSC-derived
cells. Additionally, culture under hypoxic conditions did not affect chromosomal stability [79,80],
but when prolonged in extreme conditions (1% O2 for 7 or 15 days) resulted in significantly increased
cell death [79,81].
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Table 1. The summary of studies investigating the impact of hypoxia on angiogenesis-related markers and properties of pluripotent stem cells.
Cell Type Hypoxia Level Duration # Scheme of the Experiment
Angiogenesis-Related Markers and/or Properties
Increased vs. Normoxia
(20% or 21% O2)
References
mESCs 1% O2 7 days
Undifferentiated mESCs plated on collagen IV-coated plate and
differentiated in ECDM containing Iscove’s Modified Dulbecco’s
Medium (50%), 50% Ham’s F-12 medium (50%), supplemented with N2,
B27 retinoic acid, 0.05% lipid-rich BSA, ascorbic acid (50 ng/mL), MTG
(50 ng/mL), human VEGF (50 ng/mL), human FGF2 (10 ng/mL), and
BMP4 (2 ng/mL)
CD144, PECAM1 mRNA and protein
Percentage of CD144+PECAM1+ cell population
HIF-1α protein
Glut1, Pdk1, Pdk3, Pdk4, Ldha, Etv2, Ephb2, Notch1,
Dll4 mRNA
[76]
hESCs 1% O2 7 days
Undifferentiated hESCs plated on Matrigel-coated plate in Essential 8
medium. The next day, medium replaced with ECDM containing
Iscove’s Modified Dulbecco’s Medium (50%), Ham’s F-12 medium (50%),
insulin-transferrin-selenium-X, chemically defined lipid concentrate
(1%), BSA (5 mg/mL), ascorbic acid (50 ng/mL), and 1-Thioglycerol (200
µM) supplemented with activin A (25ng/mL), BMP4 (10 ng/mL), VEGF
(50 ng/mL), CHIR (1.5 µM) and incubated for 3 days. At days 3, 5, 7
medium replaced with serum-free differentiation medium supplemented






up to 15 days
Undifferentiated hESCs cultured on ECM from human foreskin
fibroblasts under hypoxic conditions in a foreskin-fibroblast conditioned
medium composed of DMEM/F12, BME (100 µM), L-glutamine (1 mM),
NEAA (100 mM), serum replacement (20%) without changing the media
Endothelial-like morphology of the cells
VEGF, VEGFB, VEGFR2 mRNA
ANGPTL4 mRNA and protein








As above but after 5–7 days cells plated on Matrigel
and further cultured for 1–7 days
Sprouting of cellular aggregates
expressing CD34 (24 h)
Formation of cordlike structures expressing
CD34 and VEGFR2 (3 days)
More dense cordlike structures expressing
PECAM1 and vWF (7 days)
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Table 1. Cont.
Cell Type Hypoxia Level Duration # Scheme of the Experiment
Angiogenesis-Related Markers and/or Properties
Increased vs. Normoxia





3 days After 3 days from mEBs formation, mEBs were kept under hypoxicconditions for 3 days for spontaneous differentiation





After 3 days from mEBs formation, mEBs were kept under hypoxic
conditions for 2 days and seeded on a plate coated with 0.3% gelatin in
DMEM/10% FBS. Next day, the culture medium was replaced with
EGM2 medium supplemented with FBS (5%) and cells were




Vegf, Pecam1, Vegfr2, Cd144 mRNA
Junctional distribution of PECAM1 exhibiting tubular
and branching structure especially in the central
region on 7 and 14 days after reattachment
α-SMA, CD144 positive cells in the outgrowth region
on later time points, 14 days after reattachment
mEBs
Derived from mESCs
3% O2 5 to 10 days
mEBs differentiated under hypoxic conditions in methylcellulose or in
suspension for 5 to 9 days without exogenous VEGF PECAM1
+ cells
[78]
mEBs differentiated for 7 and 10 days
Adm, Ang1, Ang2, Vegfr2, Tie2, Tie1 mRNA
(by day 7)
Epo, Tie2, Tie1 mRNA (at day 10)
Differentiation of mESCs into 10-day EBs in methylcellulose
containing VEGF (25 ng/mL) and FGF2 (100 ng/mL). EBs were then
replated in collagen-type-I gel matrix for 4 days
Increased percentage of highly angiogenic,
sprouting cells
As above but with a lower concentration of FGF2 (25 ng/mL)
and VEGF (5 ng/mL or without this factor) Elevated number of highly angiogenic, sprouting cells
EBs differentiated in suspension or methylcellulose cultures in the





3% O2 7 days
hEBs transferred to hypoxic conditions 3 days after hEBs formation
(cultured in DMEM/F12 medium supplemented with serum
replacement (10%), L-glutamine (1 mM), NEAA (1%),
BME (100 mM) without FGF2 treatment
VEGFR2, PECAM1, CD144, TIE2, FGFR1,
PDGFBR mRNA
HIF-1α, VEGF, FGF2, ANG1, PDGFB/PDGF-BB on
mRNA and protein
VEGF, FGF2, PDGF-BB and, to a lesser extent ANG1
on protein (secreted)
Percentage of VEGFR1+, TIE2+, VEGFR2+, CD144+
and PECAM1+ cell populations
[80]
Cells plated on Matrigel after 7 days for additional 3 days
PECAM1+ and vWF+ cells spontaneously forming
vessel-like structures
Increased number of sprouts and, to a lesser extent,
their length
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Table 1. Cont.
Cell Type Hypoxia Level Duration # Scheme of the Experiment
Angiogenesis-Related Markers and/or Properties
Increased vs. Normoxia
(20% or 21% O2)
References
hEBs
Derived from hESCs 1% and 5% O2 7 days
Differentiating hEBs exposed to hypoxic conditions in a sealed 6.2-L
modulator incubator; half-media changes occurred
every 3 to 4 days as needed
HIF-1α protein
VEGF, GLUT1 mRNA [81]
hESCs




hPSCs plated onto collagen IV-coated plates and cultured in a
differentiation medium composed of α-MEM, FBS (10%)
and BME (0.1 mM)
Primed: cells attached in normoxic conditions for 4 hours and then
subjected to hypoxia. On day 6, differentiated cells were collected,
seeded on collagen-type-IV-coated plates in ECGM supplemented with
FBS (2%) VEGF (50 ng/mL) and SB431542
(10 µM) for an additional 6 days
Continuous: cells attached for 4 hours in normoxic conditions, and then
subjected to continuous 5% O2 conditions
After 6 days: CD34, VEGFR2, CD56 mRNA
Primed and continuous: CD144, PECAM1 mRNA;
PECAM1+ cells; lectin binding, uptake of acLDL, tube
formation on Matrigel
Continuous: endothelial-like morphology with
bundles of elongated cells and cobblestone
area-forming cells; CD144+ cells; CD144 and PDGFRβ
localized with CD144+ clusters surrounded by
PDGFRβ+ cells
[82]
hESCs and/or hiPSCs 1% and 5% O2 up to 3 days
hESC and hiPSC cells grown on an inactivated mouse embryonic feeder
layer in a growth medium consisting of 80% ES-DMEM/F12
supplemented with 20% KSR and FGF2 (4 and 10 ng/mL for hESCs and
hiPSCs, respectively). For the experiment, cells were seeded on
Matrigel-coated plates for feeder-free culturing in a conditioned medium
supplemented with the same FGF2 concentrations above. Cells were
allowed to attach in atmospheric oxygen for 24 h before the culture
under low oxygen tension.
HIF-1α protein
VEGF, ANG1, ANG2, GLUT1 mRNA [88]
List of abbreviations: acLDL—acetylated low-density lipoprotein; ACTA2—actin alpha 2, also known as alpha smooth muscle actin, α-SMA; ADM—adrenomedullin; ANG1—angiopoietin 1;
ANG2—angiopoietin 2; ANGPTL4—angiopoietin-like 4; α-MEM—Minimum Essential Medium Eagle-alpha modification; B27—serum-free supplement used to support the growth and
viability; BME—β-mercaptoethanol; BMP4—bone morphogenetic protein 4; BSA—bovine serum albumin; CD144—cluster of differentiation 144, also known as vascular endothelial
cadherin, VE-cad; CD34—cluster of differentiation 34, transmembrane phosphoglycoprotein; CD56—cluster of differentiation 56, also known as neural cell adhesion molecule, NCAM;
CHIR—specific inhibitor of glycogen synthase-3β; DLL4—delta-like 4; DMEM—Dulbecco’s Modified Eagle Medium; DMEM/F-12—Dulbecco’s Modified Eagle Medium/Nutrient Mixture
F-12; ECDM—Endothelial Cell Differentiation Medium; ECGM—endothelial cell growth media; ECM—extracellular matrix; ECs—endothelial cells; EGM2—Endothelial Cell Growth
Medium 2; EPHB2—ephrin receptor B2; EPO—erythropoietin; FBS—fetal bovine serum; FGF2—basic fibroblast growth factor, bGFG; FGFR1—fibroblast growth factor receptor 1;
GLUT1—glucose transporter 1; hEBs—human embryoid bodies; hESCs—human embryonic stem cells; HIF-1α—hypoxia-inducible factor-1α; HIF-2α—hypoxia-inducible factor-2α;
hiPSCs—human induced pluripotent stem cells; hPSCs—human pluripotent stem cells; IGF-1—insulin-like growth factor-1; KSR—knockout serum replacement; LDHA—lactate
dehydrogenase A; mEBs—mouse embryoid bodies; mESCs—mouse embryonic stem cells; MTG—monothioglycerol; mVEGFR1—membrane-bound vascular endothelial growth
factor receptor 1; N2—serum-free supplement based on Bottenstein’s N-1 formulation; NEAA—nonessential amino acids; NOTCH1—Notch homolog 1, translocation-associated;
PDGFB/PDGF-BB—platelet-derived growth-factor beta/platelet-derived growth factor beta polypeptide; PDGFBR—platelet-derived growth factor receptor beta; PDK1/3/4—pyruvate
dehydrogenase kinase 1/3/4; PECAM1—platelet endothelial cell adhesion molecule, also known as cluster of differentiation 31, CD31; SB431542—inhibitor of the activin receptor-like
kinase (ALK) receptors, ALK5, ALK4 and ALK; SDF-1—stromal cell-derived factor-1; sVEGFR1—soluble vascular endothelial growth factor receptor 1; TIE1—tyrosine kinase with
immunoglobulin-like and EGF-like domains 1; TIE2—tyrosine kinase with immunoglobulin-like and EGF-like domains 2; VCAM-1—vascular cell adhesion protein-1; VEGF—vascular
endothelial growth factor A; VEGFB—vascular endothelial growth factor B; VEGFR1—vascular endothelial growth factor receptor 1; VEGFR2—vascular endothelial growth factor
receptor 2; vWF—von Willebrand factor. #, not all analyses were performed at the endpoint of the experiment; * not directly compared to normoxia.
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5.2. Initial Exposure to Hypoxia Is Crucial for Differentiation toward ECs
Important observations were made regarding the specified hypoxia exposure period that is
needed for the maintenance of differentiation toward ECs. Tsang et al. [76] tested six variations of
normoxia and hypoxia (5% O2) period during 7 days of mESCs differentiation. It was clearly shown
that a minimum of two days of initial hypoxic conditions is required, as e.g., switching to hypoxia
after 2 first days in normoxia failed to increase the percentage of CD144+PECAM1+ population.
In line with that was the study performed on hiPSCs differentiated for 12 days in total with the
6-day-lasting hypoxic (5% O2) conditions which were either initiated at the beginning (primed 5% O2)
or at days 6–12 (secondary 5% O2) [82]. The expression of CD144 and PECAM1 in secondary conditions
was at a similar level to normoxia, unlike in the case of primed 5% O2 which resulted in profound
upregulation of these ECs markers [82]. Moreover, whereas the cells differentiated under hypoxic
conditions during the second-half of differentiation lacked any organization, primed 5% O2 resulted in
an endothelial-like morphology, namely elongated cell bundles and cobblestone area-forming cells
with CD144+ cells surrounded by platelet-derived growth factor receptor beta-positive (PDGFRβ+)
cells [82]. Hence, it might be assumed that early stages of differentiation at low oxygen tension
accelerate endothelial lineage commitment.
5.3. The Evidence for an Arterial Phenotype of ECs Differentiated under Hypoxic Conditions
There is also evidence that ECs differentiated in hypoxic conditions exhibit rather arterial- than
venous-like phenotype (aECs and vECs, respectively), similarly to embryonic development of ECs
as mentioned earlier [52]. The phenotype is mostly based on the analysis of typical markers such
as the evaluation of arterial (ephrin B2-ephrinB2 and neuropilin 1-NRP1) and venous (ephrin type-B
receptor 4-EPHB4 and neuropilin 2-NRP2) markers compared to primary arterial (HUAECs) and
venous (HUVECs) cells. The results revealed that the phenotype of hPSCs differentiated either for 6 or
12 days upon hypoxic (5% O2) conditions was more similar to HUAECs, whereas cells differentiated
under normoxic conditions did not exhibit clear identity toward either phenotype [82]. In line with that
Tsang et al. [76] demonstrated increased expression of not only ephrinB2 but also Dll4 and Notch1 with a
simultaneous decrease in the level of venous-specific CoupTFII between 3–7 days of exposure of mESCs
to 1% O2 tension. Moreover, NOTCH1 appeared to be an important regulator of aECs maturation,
consistently with literature data [52,89], as Notch1−/− cells failed to augment the aECs phenotype
but concomitantly sustained hypoxia-induced CD144+PECAM1+ population of EC progenitors [76].
The authors of the latter study emphasized the possible role of a high concentration of VEGF present in
the differentiation medium on observed effects, knowing that VEGF is a critical driver of aEC fate [90].
5.4. The Role of VEGF in Hypoxia-Induced Differentiation toward ECs
Generally, VEGF was reported to be one of the most upregulated pro-angiogenic factors upon
hypoxic conditions both on mRNA and protein (also secreted) level in the studies evaluating
differentiation toward EC lineage [49,77,79–81]. Interestingly, to assess the importance of VEGF,
Shin et al. [80] cultured hESCs-derived EBs with 50 ng VEGF for 10 days under normoxia what resulted
in 1.2–3.4 times higher protein levels of VEGFR1, VEGFR2, Tie2, CD144 and PECAM1 in comparison to
control hEBs. Moreover, VEGF-treated hEBs spontaneously formed vessel-like structures, similarly to
hEBs kept under hypoxic conditions, and exhibited increased sprouted capillary length when cultured
on Matrigel compared to control hEBs. Though it indicates that VEGF promotes vascular lineage cell
development within hEBs, more direct comparison to hypoxic conditions would be needed to see
if VEGF supplementation is enough to mimic or even favor the effects observed upon low oxygen
environment and hence, if it could be used as an alternative approach to trigger EC commitment.
A different strategy was studied by Lee et al. [77], who nicely demonstrated that treatment of mEBs with
neutralizing antibodies against mouse VEGF (50 µg/mL) after 2-day-lasting hypoxic exposure decreased
expression of CD144 and PECAM1. It suggests that hypoxia stimulates the EBs to produce VEGF
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which mediates endothelial differentiation, most probably through autocrine and/or paracrine manner.
Finally, Han et al. [78] proved that extrinsic and intrinsic inhibition of VEGF attenuates, but does
not abolish the development of vascular lineage cells from EBs as the result of hypoxia, pointing
out that VEGF is important, but not a sole player in hypoxia-mediated angiogenic differentiation.
The significance of VEGF receptors modulation in controlling the formation of the vascular network
driven by low oxygen tension was emphasized as well [78].
5.5. HIF-1α as a Master Regulator of Hypoxia-Driven Differentiation toward ECs
As indicated earlier, the upstream regulator of VEGF, but also other angiogenic factors, is HIF-1 [8,9],
with HIF-1α being potently upregulated upon differentiation of pluripotent cells in low oxygen
tension [76,77,80,81].
By utilizing YC1, a HIF-1 blocker, a dose-dependent decrease of Vegf, Pecam1, Vegfr2, and Cd144 in
mEBs exposed to hypoxia was observed [77]. Similar results showing diminished HIF-1 target proteins
and other ECs markers were obtained by the application of echinomycin, the HIF-1 transcriptional
activity inhibitor [80], as well as by specific inhibition of HIF-1α using shRNA [77], emphasizing the
critical role of HIF-1α in the regulation of low oxygen environment-induced vascular differentiation of
pluripotent stem cells.
Noteworthy, HIF-1α appears to be differentially regulated depending on the hypoxia exposure
period. In 2008, Cameron et al. [81] were unexpectedly not able to detect HIF-1α protein in hEBs
at day 16 of the differentiation under constant hypoxic conditions (1% and 5% O2). This puzzling
result prompted the authors to apply a shorter period of hypoxia exposure, which started at day
11 of differentiation and lasted for 7 days. In that case, HIF-1α was visible already after 12 hours
(unlike under normoxia), reached the peak between 1st and 2nd day and then was gradually reduced
by the 5th and 7th day (in both undifferentiated hESCs and hEBs), confirming temporal HIF-1α
accumulation, despite constantly low oxygen tension [82]. Concomitantly, HIF-1α target genes, VEGF,
and GLUT1 were increased upon the hypoxic environment (1% and 5% O2) as compared with 21% O2
at each time point [81]. A similar pattern of HIF-1α accumulation together with the upregulation of
VEGF and GLUT1 mRNA was observed irrespectively of the stage of the differentiation (started either
at day 1, 4, 7, or 11) at which the 7-day-lasting hypoxic (1% O2) conditions were initiated [81].
More mechanistic insight into the HIF-1α regulation was provided by Tsang et al. [76].
An upregulation of HIF-1α together with its target genes, namely Glut1, Pdk1, Pdk3, Pdk4, Ldha
during the early phase of differentiation under hypoxia (1% O2) was demonstrated. Of note, precise
deletion of HIF-1α using CRISPR/Cas9 prominently abolished ECs differentiation as revealed by
almost a 6-fold reduced percentage of a CD144+/PECAM1+ cell population in HIF1a-KO cells in
comparison to control cells [76]. Interestingly, Etv2, one of the Ets transcription factors regulating ECs
differentiation [91], was markedly, but temporarily elevated upon hypoxia (7-fold increase at 2–3 days
and decrease at day 5 to the level comparable to normoxic conditions). HIF-1α was verified to bind
to Etv2 promoter upon low oxygen tension [76]. A deletion of Etv2 was associated with reduced EC
differentiation, similarly to the effect observed in the case of HIF1a-KO cells. This points out HIF-1α
and Etv2 as factors required for hypoxia-mediated induction of EC progenitor differentiation and
their maturation as both HIF-1a-KO and Etv2-KO cells prevented upregulation of aECs markers upon
hypoxic conditions possibly through the regulation of NOTCH1 level [76].
Additionally, a comprehensive study was performed by Lee et al. [77] who applied short hypoxia
exposure time and unraveled novel mechanisms driven by HIF-1α, which function is not restricted to
the induction of the expression of certain genes upon hypoxia, as it may also act as a transcriptional
repressor by binding to reverse HRE sequences (rHRE). Surprisingly, four such rHRE sequences specific
for HIF-1α were found in the Oct4 promoter, and HIF-1α was demonstrated to decrease Oct4 by binding
to three of them [77]. Accordingly, transfection with HIF-1α (together with HIF-1β) under normoxia or
knockdown by shHIF1α upon hypoxia resulted in a decrease or elevation of Oct4, respectively [77].
Finally, overexpression of Oct4 (decreased upon hypoxia) attenuated expression of not only EC markers
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but also endodermal marker, Troma1 (increased upon hypoxia), suggesting its negative impact on stem
cell differentiation in low oxygen environment [77]. This might be particularly important in the context
of controversial issues related to the influence of hypoxia on retaining stemness or promoting stem cell
differentiation, what, in this particular case, indicates to be at least partially regulated by HIF-1α.
Lastly, though the effect of HIF-1β (Arnt) was not thoroughly studied, it should be noted that it is
essential for maintaining HIF transcriptional activity. The loss of Arnt was shown to affect vascular
differentiation of embryonic stem cells upon hypoxic conditions [78]. This indicates the integral role of
both HIF-1α and HIF-1β in acquiring angiogenic features of cells in a low oxygen environment.
6. hiPSC-ECs in Disease Modeling
One of the most important applications of hiPSCs is to use them as a tool to better understand
the mechanisms responsible for the origin and development of various diseases, but also to test
the activity of potential therapeutic compounds and drug cytotoxicity in a personalized manner.
Importantly, these models provide human-relevant information on disease mechanisms or drug
responses, as compared to various animal models. As discussed above, hiPSCs demonstrate the
capacity to efficiently differentiate into various cell types including ECs [92]. Importantly, many studies
have already confirmed that patient-specific hiPSC-derived ECs recapitulate the specific pathological
phenotype observed in a particular disease, either with a known genetic background or complex
etiology and systemic course [93,94]. The most tractable diseases to model in vitro are those caused
by mutations in single genes (monogenic diseases) [95]. The results from such studies give more
relevant information, especially in case the modeling is conducted with the usage of isogenic cell lines,
which differ only at the gene of interest. However, the more prevalent disorders of the vasculature,
like diabetes, are caused by various factors, both genetic and environmental. Such complex diseases
additionally affect different cell types and therefore are more challenging to model in vitro [75].
6.1. Monogenic Diseases
Pioneering cardiovascular disease modeling studies used the general comparison between
hiPSC-derived ECs from healthy and diseased individuals. Such an approach was taken to study
fibrodysplasia ossificans progressiva (FOP), which is a disease of heterotopic ossification caused by
activating mutation in activin A type I receptor (ACVR1). Comparing hiPSC-ECs from patients with
FOP to healthy control cells, the authors found increased expression of fibroblastic genes and collagen
1/2, together with increased SMAD 1/5/8 signaling upon BMP4 stimulation [96]. A similar approach
was used in the modeling of Moyamoya disease (MMD), which is a slow progressive steno-occlusive
condition arising in the cerebral internal carotid artery. The disease was associated with a mutation
in ring finger protein 213 (RNF213), as such mutations were found in 95% of patients with MMD.
Using hiPSC-ECs from MMD patients, as compared to cells derived from healthy individuals,
an impairment in angiogenic response together with downregulation of cytoskeleton-related proteins
was found [97]. In the study of Sa et al. [98], ECs differentiated from hiPSCs of patients with heritable or
idiopathic pulmonary arterial hypertension (PAH) were compared to hiPSCs from control individuals,
while observed changes were additionally confirmed in primary pulmonary arterial ECs from the same
patients. Importantly, both models (primary cells and iPSCs) gave similar results with ECs from PAH
patients being associated with reduced adhesion, migration, survival, and tube-formation capacity in
comparison to control cells. Thus, the authors concluded that iPSC-ECs are useful surrogates and can
be used to uncover novel features related to disease mechanisms [98].
Along with the development of advanced gene-editing tools such as CRISPR/Cas9, new strategies
allowing for the generation of isogenic cell lines that differ in a single gene provided a new powerful
tool linking genotype to phenotype in different cardiovascular diseases. For instance, to understand
the effect of bone morphogenetic protein receptor 2 (BMPR2) mutations in ECs, Gu et al. [99] used
ECs differentiated from hiPSCs of patients with familial PAH (FPAH), CRISPR/Cas9 corrected FPAH,
healthy individual, and unaffected BMPR2 mutation carrier. The results showed that ECs from FPAH
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patients are dysfunctional and with decreased survival as compared to BMPR2 corrected cells and
the ones obtained from unaffected mutation carriers. This suggests that additional BMPR2 modifiers
play a role in the protection of unaffected carriers from FPAH phenotype [99]. Moreover, using FPAH
iPSC-ECs carrying BMPR2 mutation and CRISPR/Cas9 corrected cells, the authors were able to show
the importance of the noncanonical p38 signaling pathway in response to BMP4 [99]. Looking for the
disease mechanisms of calcific aortic valve disease, which is the second most prevalent cause for heart
surgery, iPSCs isogenic cell lines were used. Comparing hiPSC-ECs from patients to the respective
corrected isogenic lines, the epigenetic mechanism of NOTCH1 haploinsufficiency on activation
of osteogenesis gene expression and inflammatory gene networks was found [100]. In a different
study, CRISPR/Cas9 targeted mutation was used to prove the disease phenotype suspected to be
caused by the cardiac-specific transcription factor GATA4 in patients with bicuspid aortic valve (BAV),
a heritable congenital heart disease. GATA4 was identified as a potential target while surveying the
genome of such patients, and its mutation was associated with impaired endothelial-to-mesenchymal
transition, a process important for normal aortic valve formation [101]. Similarly, in our studies using
hiPSCs isogenic lines generated through the introduction of mutation in hepatocyte nuclear factor
1A (HNF1A), we aimed to model the endothelial state of patients with maturity onset diabetes of
the young (HNF1A-MODY) [92]. In our hands, hiPSC-ECs expressed typical endothelial markers,
exerted angiogenic functionality, properly responded to inflammatory cytokines as well as shear stress
(Figure 5). Vascular complications are quite common in this MODY subtype and we showed that
hiPSC-derived ECs with a monoallelic mutation in the HNF1A gene, as occurring in HNF1A-MODY
patients, have increased vascular permeability in comparison to ECs derived from the isogenic
control line. The effect was even stronger in line with biallelic mutation of the gene, suggesting a
certain predisposition of HNF1A-MODY patients to microvascular complications [92]. Currently,
we are also using hiPSC-ECs to better understand the dysregulation of angiogenesis in Duchenne
muscular dystrophy (DMD). Using the CRISPR/Cas9 method we established an isogenic cell line with
deleted DMD exon 50, resulting in a complete absence of dystrophin, a mutation frequently found
in DMD patients. Our ongoing experiments indicate that hiPSC-ECs are a great tool to study the
angiogenesis-related changes in the pathology of DMD.
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Figure 5. Cha acterization of hiPSC-ECs. Endot lial cells after differentiation from hiPSCs express
endothelial markers (e.g., VE-cadherin, Angiopoietin 1-Ang1) and exert potent angiogenic capacity
(they form tubule-like structures on Matrigel and spheres in endothelial sprouting assay). hiPSC-ECs
properly respond to proinflammatory cytokines (the increase in ICAM-1 (intercellular adhesion
molecule 1) expression is evident by flow cytometry analysis) and shear stress.
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6.2. Complex Vascular Disease—Diabetes
Although attempts have been made to model the effects of metabolic diseases using hiPSCs from
diabetic patients, no studies have explored the effect of diabetes on ECs [102]. Diabetes is a group of
metabolic diseases that affects over 300 million people worldwide [103]. However, the cause of the
disease is multifactorial, including both environmental and genetic factors. A great part of the morbidity
and mortality associated with diabetes results from chronic vascular complications. Even though
hyperglycemia was considered as the main causative for diabetes-related endothelial dysfunction,
recent studies show that vascular complications can still occur in patients independent of the diabetes
duration and their glycemic status [104]. For instance, Drawnel and colleagues showed that culturing
cardiomyocytes derived from control hiPSCs under hyperglycemic conditions led to the development
of features characteristic for diabetic cardiomyopathy, in particular, hypertrophy, dysregulation of
sarcomeres, abnormal electrophysiological, and metabolic properties as well as increased oxidative
stress [94]. Importantly, the same phenotype was displayed by cells obtained from type 2 diabetes
(T2D) patients even under normoglycemic conditions, and the extent of pathophysiological changes
correlated with the advancement of the disease [94]. Currently, limited studies have addressed the
issue of endothelial dysfunction in relation to diabetes, using various approaches that limit the number
of possible causative factors. Knowing that AKT2 kinase (PKB) is an important mediator of insulin
signaling and its disturbance leads to early onset diabetes and obesity, Roudnicky et al. used ECs
derived from hiPSCs with dysregulated AKT2, to model the endothelial dysfunction [102]. The results
showed that such cells have an increased proinflammatory response, which may further contribute
to coronary artery disease [102]. In a different study, RNA-binding protein Quaking-7 (QKI-7) was
found to be upregulated in iPSC-ECs after exposure to hyperglycemia and in hiPSC-ECs from diabetic
patients. QKI-7 upregulation was correlated with disrupted cell barrier, enhanced monocyte adhesion,
and compromised angiogenesis, suggesting this protein as a possible new strategy for the treatment
of diabetic vascular complications [105]. Another approach could be the use of information from
genome-wide association studies (GWAS), which have successfully identified a large number of
genetic loci associated with risks of complex traits in cardiovascular diseases. Recently, at least
57 independent loci within the human genome were identified as risk factors for developing type
1 diabetes (T1D) [106]. However, it is not possible to study one gene at a time without incurring
significant epistatic effects from other risk genes. The likelihood of finding two individuals differing at
only one risk gene, while having identical variants at the remaining 56 risk regions is infinitely small.
Therefore, the additional downstream analysis should be performed to narrow the list of potential
risk factors. In addition to the number of variants and overlapping pathways, there are additional
layers of complexity at the cellular level. To begin to address these challenges, the researchers need
robust platforms to study the effects of individual risk alleles in various cell types under controlled
conditions, which could be achieved through a hiPSCs-based approach [106]. Overall, there are
encouraging reports suggesting that this complex metabolic syndrome can be effectively modeled with
hiPSCs technology. However, there is a current lack of information, whether these in vitro models can
fully reproduce dysfunctional phenotype through hiPSC-derived ECs [107].
7. Application of hiPSC-ECs for Ischemia-Related Disorders
As indicated above, iPSC-ECs can function as an excellent tool for disease modeling and can
be used in pathophysiological studies to model endothelium-related diseases. The pathogenesis of
vascular diseases is associated with the altered functioning of not only ECs but also other cells building
blood vessels, like vascular smooth muscle cells (VSMCs). They can be both derived from iPSCs and
applied to mimic vascular abnormalities to better understand the molecular mechanisms underlying
human diseases. hiPSC-ECs are highly relevant in both disease modeling and therapeutic interventions
with their beneficial potential already tested in many preclinical animal studies resembling the
conditions associated with hypoxia, such as wound healing [108–111], hindlimb ischemia [86,110–116],
retinopathy [117–119], and myocardial infarction [120–123] (Figure 6). In these studies, it was
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demonstrated that the transplantation of hiPSC-ECs improved the disease condition through either
integration into the host vasculature or paracrine activation.
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7.1. Wound Healing
Angiogenesis is an essential component of the normal wound healing process, as it restores
perfusion to damaged tissues and provides key nutrients. On the other hand, the proper vascularization
is reduced in the hypoxic environment of chronic wounds. Sever l studies util zed iPSC-ECs in both
non-ischemic and isch mic wou d healing, i dicating their role in the facilitation of the blood vessel
formation and perfusion to injured tissues. Moreover, the usage of hiPSC-ECs may be a promising
strategy for the treatment of diabetic wounds, in which the low oxygen environment greatly contributes
to observed complications [108–111].
In the above-mentioned interve tions, hiPSC-ECs were delivered ostly by intradermal injection
or topical application. In a murine model of wound healing, improved blood perfusion in wounds,
and increased vessel density was observed after hiPSC-ECs treatment [109]. The abundance of
PECAM1-positive vessels was confirmed in wounds at both 7 and 14 days after the topical application
of 5 × 105 hiPSC-ECs. The expression of different angiogenic markers was significantly increased,
and the collagen content was also prominently higher after hiPSC-EC delivery. The calculation of
wound closure in the following days after cell application reveale statistically significant improvement
at day 4 and 10 post-injury and hiPSC-EC-treat d ounds achieved complete closure 4 day earlier
than in control conditions [109].
In a different approach, Kim et al. [108] tested concomitant delivery of 6 × 104 hiPSC-ECs and
4 × 104 hiPSC-SMCs. Such combinatory treatment was quite effective, and increased angiogenesis
prominently supported wound closure. The comparison of the angiogenic secretome of hiPSC-ECs
and HUVECs showed grea er relea e of VEGF, FGF-4, epidermal growth factor (EGF) by ECs
differentiate from hiPSCs. Consistent with in vitro data, enhanced in vivo neovascularization in
groups treated with hiPSCs-derived ECs and SMCs in comparison to HUVECs mixed with human
vascular SMCs (HVSMCs) was observed. Moreover, the co-implantation of hiPSC-ECs and hiPSC-SMCs
gave better results in terms of vascular perfusion and arteriole density compared with mice treated
with hiPSC-ECs alone [108].
Another option to increase the effectiveness of hiPSC-ECs delivery to the ischemic milieu and
overcome the problem with the low rate of in vivo cell survival might depend on the usage of special
biomaterials/scaffolds. Culturing of hiPSC-ECs on electrospun polycaprolactone (PCL)/gelatin scaffold
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(70:30) for seven days and then implanting cells in vivo to wild-type FVB/n mice improved cell
survival up to 3 days, whereas the engraftment of the hiPSC-ECs without any modifications was very
poor, and their viability dramatically decreased already 1 hour after injection [110]. The enhanced
recruitment of macrophages in the case of scaffold-assisted hiPSC-ECs delivery was also evident.
Of note, a similar number of cells as in the above-mentioned studies (~3 × 105) was transplanted into
severe combined immunodeficient (SCID) mice (5 × 105) [109], in which quite good efficacy of cells
without any biomaterials was described. These differences underline enhanced cell engraftment in
SCID mice in comparison to mice with a properly working immune system, but still poor cell survival
represents a major limitation to the long-term therapy.
Another example of supporting material used to enhance hiPSC-ECs bioavailability can be
acrylated hyaluronic acid, which was shown to promote the delivery of hiPSC-ECs in a model of
diabetic wounds in mice [111]. Although it is well established that biomaterials exert beneficial effects
on hiPSC-ECs delivery, it has to be taken into consideration that the technical parameters of the
scaffolds have to be determined carefully, as e.g., the diameter and alignment of nanofibrillar collagen
scaffolds may affect the properties of hiPSC-ECs (as it was shown that biomaterials greatly influence
EC properties in normal and hypoxic conditions [124]). Taking all into account, hiPSC-ECs provide
a great therapeutic option for the treatment of (hypoxic) wounds, but the optimal delivery and the
enhancement of their in vivo survival in chronic wounds by the use of the appropriate biomaterials
warrants further research.
7.2. Hindlimb Ischemia
Critical limb ischemia (CLI) is an advanced stage of peripheral arterial disease (PAD) manifested
by chronic ischemic pain at rest, ulcerations, or limb necrosis [125]. The therapeutic potential of
hESC-ECs/hiPSC-ECs has been demonstrated using animal models of CLI (mostly hindlimb ischemia
model—HLI, obtained by femoral artery ligation [126]), in which the ischemic tissue has to deal with
insufficient oxygen and nutrient supply.
Intramuscular injection of hESC-ECs into ischemic limbs one day after surgical induction of HLI in
athymic mice resulted in accelerated capillary and arteriole densities and increased blood perfusion [86].
Of importance, the functional effect of this therapy was evident, as the improvement of ischemic limb
salvage by hESC-EC transplantation was demonstrated—in the group of medium-treated animals,
9/10 mice lost the limb, whereas after cell therapy, limb loss was seen only in 3 out of 11 animals.
The beneficial outcome of hESC-ECs in the ischemic leg was mediated through the paracrine effect
and increased production of the pro-angiogenic factors (VEGF, Ang1, FGF2) together with the direct
incorporation of transplanted cells into vascular structures. This led to the functional recovery of
ischemic tissue and normalization of the pathological vascularization [86]. Of note, the favorable
result (enhanced reperfusion in the ischemic limb) was demonstrated for hESC-ECs and hiPSC-ECs in
comparison to HUVECs [116].
Lee et al. [113] showed that the combination of hiPSC-ECs with appropriate biomaterials
may increase the efficacy of cell therapy also in chronic HLI. Although blood flow was
significantly improved in mice after femoral artery ligation receiving either hiPSC-ECs or
hiPSC-encapsulated in special nanomatrix gel (in comparison to medium-, biomaterial-, HUVECs- and
HUVECs/biomaterial-treated animals), the quantitative analysis of vascular density in hindlimb muscles
revealed the superiority of biomaterial-enhanced hiPSC-ECs delivery. The statistically significant
difference in cell engraftment of ischemic tissues was found for hiPSC-ECs encapsulated within the
nanomatrix gel in comparison to non-facilitated cell delivery. A similar study was performed by
Foster et al. [114], who used the recombinant hydrogel, termed SHIELD (Shear-thinning Hydrogel for
Injectable Encapsulation and Long-term Delivery) to increase cell survival and therapeutic efficacy of
hiPSC-ECs in the murine HLI model of PAD.
The therapeutic potential of hiPSC-ECs might be related to the appropriate way of cell delivery.
However, the comparison of intramuscular (IM), intra-femoral artery (IA), or intra-femoral vein (IV)
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injections of mESC-ECs (5 × 104 cells for IM and IA as well as 5 × 105 cells for IV route) in a syngeneic
model of HLI confirmed the engraftment of mESC-ECs into the limb vasculature after 2 weeks as well
as improved limb perfusion and neovascularization regardless of route of administration [115].
In summary, iPSC-ECs therapy for limb ischemia was shown to be safe, well-tolerated,
and effective. However, the increased survival and enhanced engraftment of cells in vivo was
noted after biomaterial-facilitated delivery.
7.3. Retinopathy
Retinal vascular abnormalities, like diabetic retinopathy and retinal vein occlusion, are associated
with retinal ischemia and degeneration, resulting in vision loss. Cell therapy aiming at the restoration of
the function of both damaged retinal vasculature and neurons was tested in several studies [117–119].
Park et al. [117] found that hiPSC-derived CD31+CD146+ vascular progenitors obtained from
cord blood were effective in homing and integrating into injured retinal capillaries. The incorporation
into damaged vessels lasted up to 45 days, and the repairment of the non-functional vasculature was
therefore achieved. In contrast, vascular progenitors derived from iPSCs obtained from fibroblasts
did not exert such capabilities [117]. In contrast, in the oxygen-induced retinopathy (OIR) in C57/BL6
neonatal pups, prominent angiogenic response and reduction of the post-injury avascular area were
also observed in the retinas after intravitreal injection of 1 × 105 iPSC-derived ECs with properties of
the cord-blood endothelial colony-forming cells (ECFC) [118].
In a very recent paper by Cho et al. [119], the comparison of the angiogenic potential of hiPSC-ECs
with mature human retinal endothelial cells (HRECs) in response to hypoxia was performed. In the
mouse model of OIR, only hiPSC-EC colocalized with host vessels, and this effect was dependent on
the stromal cell-derived factor-1α (SDF-1α)/CXCR4 axis. Interestingly, the procedure was performed
not only in immunocompetent C57BL/6 but also in immunodeficient NOD/SCID mice, and the
authors reported a similar superior effect of colocalization, which did not depend on the mouse
strain/immune system. It should be noted that the possible immunogenic effect of ECs delivery to
immunocompetent mice (not subjected to immunosuppression) was not taken into consideration in
this study, which is an important issue when such experiments are conducted [127].
As relatively little attention has been given to the use of hiPSC-derived cells in ischemic retinal
conditions, further research is needed to confirm its utility in the restoration of retinal perfusion and
retinal vascular regeneration attenuating ischemic damage.
7.4. Myocardial Infarction
Cardiovascular diseases are the leading cause of death worldwide and new therapies targeting
diseased hearts are undeniably needed. iPSC technology offers a range of possibilities. In the
mammalian heart, cardiomyocytes (CMs), ECs, fibroblasts (FBs), and perivascular cells are essential
for normal heart homeostasis. Depending on the method of the estimation, the relative ratios
of these cell subtypes greatly vary and may be influenced by numerous conditions, including
age [128,129]. Nevertheless, in terms of myocardial infarction (MI), trials are mostly conducted
with CMs (including hiPSC-CMs) but the combined stem cell therapy, with concomitant delivery of
hiPSC-ECs and hiPSC-SMCs, has the greater potential to form stabilized functional vessels providing
long-lasting support to the patients’ blood vessel system [121]. Besides, hiPSC-derived cells of multiple
cardiovascular lineages mixed with biomaterials allowing physical support for cells and being the
origin of factors enhancing differentiation and/or functional maturation of hiPSC were tested in
animal models. As mentioned earlier, the various components/properties of such biomaterials may
greatly affect the biocompatibility with different cell types/conditions.
After studies with canine-derived iPSC-ECs in an immunodeficient mouse model of MI showing
short-term improvement in myocardial contractility [130], human cells were also investigated in
various experimental settings. Prado-Lopez et al. [79] utilized endothelial-like cells generated from
hESCs differentiated in hypoxia (as discussed earlier) to check their functionality in a rodent model of
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acute MI. After induction of MI, rats were randomized to receive saline or 3 × 105 hESC-ECs per animal
(injected at five distinct points of the infarct border zone). Echocardiograph parameters measured
after 2 and 4 weeks after transplant, as well as histological analysis, showed functional heart recovery,
decreased infarct size, and a lower rate of fibrosis in animals receiving hESC-ECs in comparison to
saline-treated rats [79].
In a porcine model of postinfarction left ventricular (LV) remodeling, Xiong et al. [120] tested
delivery of combined transplantation of hESC-ECs and hESC-SMCs with a fibrin three-dimensional
(3D) porous scaffold biomatrix. Significant engraftment of hESC-derived cells resulted in the functional
benefits: increased neovascularization, LV function improvement, and reduction of infarct size
that occurred predominantly after fibrin patch enhanced delivery. The additional modification
was done by Ye at al., as a 3D fibrin patch supplemented with insulin-like growth factor (IGF-1,
the cytoprotective agent, which can improve cell survival rate) was used for intramyocardial
transplantation of hiPSC-derived CMs, ECs, and SMCs (2 × 106 of each cell type, 6 × 106 cells in total)
in the porcine model of ischemia-reperfusion (IR) injury [121]. Such tri-lineage, IGF-1-containing fibrin
patch-enhanced cell transplantation resulted in the abundance of PECAM1+ structures, improved LV
function, decreased infarct size, and apoptosis. Moreover, the development of new technologies offered
delivery of various cardiovascular cell populations (including iPSC-ECs) using a cell sheet technology
what resulted in the creation of so-called cardiac tissue sheets (CTSs), which were successfully applied
in rat models of MI with mouse ESC- [122] and human iPSC-derived cells [123].
In summary, the application of hiPSC-ECs offers a unique opportunity for the treatment of
hypoxia-related disorders but still, this method is considered innovative and more studies, both in
animals and finally in humans, remain to be performed.
8. Limitations and Future Perspectives
Although hiPSC-ECs are suggested to be used as a tool to study patient-specific vascular
diseases, their application for personalized medicine is still limited. iPSC differentiation protocols
to ECs are not fully optimized, and various schemes are proposed, also in the context of hypoxia
application to increase the differentiation efficiency. The variability in the obtained cells may be
related to the existence of heterogeneous populations in differentiated iPSC-ECs with a relatively
low number of bona fide ECs. Paik et al. [131] have found that during differentiation, in addition
to iPSC-ECs expressing endothelial-specific genes, the non-endothelial cell types of a mesodermal
lineage, e.g., cardiomyocyte-like cells, hepatic-like cells, and vascular smooth muscle cells are generated.
Moreover, using droplet-based single-cell RNA-sequencing (scRNA-seq), the authors identified four
major (distinct) subpopulations, namely metabolically active, immune-responsive, arterial-specific,
and activated ECs which were enriched in Claudin-5 (CLDN5), Apelin Receptor (APLNR), Gap Junction
Protein Alpha 5 (GJA5), and Endocan (ESM1) genes, respectively. Moreover, the issue of
direct specification toward arterial, venous, and lymphatic phenotype was addressed in several
studies [132,133]. Uenishi et al. described NOTCH-mediated specification of iPSCs to arterial-type
endothelium [132] whereas D’Souza et al. have found that differentiated CD144+CD31+CD34+ ECs
are heterogeneous and include three major subsets with not only distinct hematogenic properties but
also various capacities to give rise to arterial, venous, and lymphatic lineages [133]. Of note, not only
differences related to the vessel type should be taken into consideration during iPSC-ECs studies, as the
functional heterogeneity depending on the tissue in which ECs reside are also important. The detailed
analysis of the data from tissue-specific mouse ECs generated by the Tabula Muris consortium [134]
identified genes and molecular pathways that govern the organ-specific role of ECs. Moreover, it was
observed that the subsets of ECs within certain tissues are sex-specific [135]. These results may be
helpful in the future analysis of the diversity of human ECs and utilization of hiPSC-ECs in targeted,
tissue-specific drug testing and studies of sex-specific cardiovascular disease models and treatments.
Lastly, it is worth mentioning ECFC or “endothelial outgrowth cells” with well-defined
characteristics and intrinsic angiogenic potential, which are now considered as true endothelial
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progenitors that can be obtained from numerous sources, ranging from the cord and peripheral blood
to lungs and placenta [136–138]. Importantly, a growing body of evidence suggests the therapeutic
potential of ECFC in, amongst others, hematological disorders, ischemic heart disease, and diabetes
(recently reviewed in: [139,140]). In the context of iPSCs, as mentioned earlier in the text, the group of
Prasain et al. described a protocol for differentiation of human iPSCs to cells similar to ECFC, which
were able to repair mouse ischemic retina and limb [118]. It would be of particular interest to study if
the effects of iPSC-derived ECFC infusions mimic or even outperform ECFC obtained with the standard
methods, which creates a novel, unexplored so far research area with great clinical applications.
9. Conclusions
hiPSC-ECs are a promising source of cells that may be used to investigate vascular development and
endothelial function. Their role in both disease studies and therapeutic interventions is beyond doubt,
but the future work should concentrate on the development of the appropriate, organ-specific
vascular cell differentiation protocols that have to be applied to obtain arterial, venous, and lymphatic
specifications. These will help to realize the full potential of hiPSC-ECs in precision medicine and
hypoxia-driven cardiovascular disorders.
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